- Home
- ANET vs GILD Comparison
ANET vs GILD Comparison
Compare ANET & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANET
- GILD
- Stock Information
- Founded
- ANET 2004
- GILD 1987
- Country
- ANET United States
- GILD United States
- Employees
- ANET N/A
- GILD N/A
- Industry
- ANET Computer Communications Equipment
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANET Telecommunications
- GILD Health Care
- Exchange
- ANET Nasdaq
- GILD Nasdaq
- Market Cap
- ANET 119.2B
- GILD 110.9B
- IPO Year
- ANET 2014
- GILD 1992
- Fundamental
- Price
- ANET $395.02
- GILD $92.79
- Analyst Decision
- ANET Buy
- GILD Buy
- Analyst Count
- ANET 20
- GILD 22
- Target Price
- ANET $385.67
- GILD $91.40
- AVG Volume (30 Days)
- ANET 1.9M
- GILD 6.6M
- Earning Date
- ANET 11-07-2024
- GILD 11-06-2024
- Dividend Yield
- ANET N/A
- GILD 3.33%
- EPS Growth
- ANET 38.55
- GILD N/A
- EPS
- ANET 8.33
- GILD 0.10
- Revenue
- ANET $6,613,147,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- ANET $19.25
- GILD $5.71
- Revenue Next Year
- ANET $18.53
- GILD $0.37
- P/E Ratio
- ANET $47.43
- GILD $953.88
- Revenue Growth
- ANET 18.19
- GILD 3.31
- 52 Week Low
- ANET $208.00
- GILD $62.07
- 52 Week High
- ANET $431.97
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- ANET 48.71
- GILD 74.53
- Support Level
- ANET $390.22
- GILD $89.01
- Resistance Level
- ANET $431.97
- GILD $98.90
- Average True Range (ATR)
- ANET 10.62
- GILD 1.73
- MACD
- ANET -1.68
- GILD 0.70
- Stochastic Oscillator
- ANET 26.23
- GILD 77.87
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.